Paragonix Technologies, Inc.

Paragonix Technologies, Inc. has been granted 31 US utility patents between 2015 and 2025, placing Paragonix Technologies, Inc. at rank #10,134 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.7 claims per patent with primary concentration in A01N (PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS). As a US Corporation, Paragonix Technologies, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 49.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 22 grants, compared with 9 in the 2015–2019 window, a +144% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Paragonix Technologies, Inc.'s 13.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Paragonix Technologies, Inc. against peers pursuing similar technology classes.